COMPANY

Qingdao Biopeptek Co., Ltd.

Qingdao Biopeptek Co., Ltd.: bulk ingredient labeler for Afamelanotide, BPC-157, Bremelanotide, Cagrilintide, CJC-1295, Desmopressin, DSIP, Dulaglutide, GHRP-6, Glutathione, Ipamorelin, KPV, Lanreotide, Liraglutide, Melanotan II, MOTS-c, Oxytocin, Pramlintide, Retatrutide, Semaglutide, Sermorelin, Setmelanotide, Tesamorelin, Tirzepatide, as stated by public registers.

BULK INGREDIENT LABELER

Lists the bulk active ingredient with FDA (NDC directory).

AfamelanotideAfamelanotide, BULK INGREDIENT Regulator openFDA
BPC-157BPC-157 Acetate, BULK INGREDIENT Regulator openFDA
BremelanotideBremelanotide Acetate, BULK INGREDIENT Regulator openFDA
CagrilintideCagrilintide, BULK INGREDIENT Regulator openFDA
CJC-1295CJC-1295 Acetate, BULK INGREDIENT Regulator openFDA
DesmopressinDesmopressin Acetate, BULK INGREDIENT Regulator openFDA
DSIPDSIP Acetate, BULK INGREDIENT Regulator openFDA
DulaglutideDulaglutide, BULK INGREDIENT Regulator openFDA
GHRP-6GHRP-6 Acetate, BULK INGREDIENT Regulator openFDA
GlutathioneGlutathione, BULK INGREDIENT Regulator openFDA
IpamorelinIPAMORELIN Acetate, BULK INGREDIENT Regulator openFDA
KPVKPV, BULK INGREDIENT Regulator openFDA
LanreotideLanreotide Acetate, BULK INGREDIENT Regulator openFDA
LiraglutideLiraglutide, BULK INGREDIENT Regulator openFDA
Melanotan IIMELANOTAN II, BULK INGREDIENT Regulator openFDA
MOTS-cMOTS-c Acetate, BULK INGREDIENT Regulator openFDA
OxytocinOxytocin, BULK INGREDIENT Regulator openFDA
PramlintidePramlintide, BULK INGREDIENT Regulator openFDA
RetatrutideRetatrutide, BULK INGREDIENT Regulator openFDA
SemaglutideSemaglutide, BULK INGREDIENT Regulator openFDA
SermorelinSermorelin Acetate, BULK INGREDIENT Regulator openFDA
SetmelanotideSetmelanotide Acetate, BULK INGREDIENT Regulator openFDA
TesamorelinTesamorelin Acetate, BULK INGREDIENT Regulator openFDA
TirzepatideTirzepatide, BULK INGREDIENT Regulator openFDA

What a register states, not an endorsement or an accusation by this site. All companies.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.